Sanjay Raj

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean Abraham, Karen Pinilla, Alimu Dayimu et al. · Nature · 2024 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of the efficacy of probiotics in plaque reduction and gingival health maintenance among school children - A Randomized Control Trial.

R Muthu Karuppaiah, Suma P. Shankar, Sanjay Raj et al. · PubMed · 2013 · 39 citations

Dentistry, Oral Health Sciences, Periodontology +16